The glucagon-like peptide 1 receptor agonist enhances intrinsic peroxisome proliferator-activated receptor γ activity in endothelial cells.
Biochem Biophys Res Commun · 2014
Last updated 2026-05-28In lab tests, a GLP-1 drug (exendin-4) increased the activity of a protein called PPARγ in human blood vessel cells by about 20% compared to untreated cells. The effect peaked 12 hours after treatment, and blocking a related signaling pathway stopped this increase. The findings suggest GLP-1 may help reduce inflammation in blood vessels through this mechanism.
AI summary of the abstract below.
| Journal | Biochem Biophys Res Commun, 2014 |
|---|---|
| Citations | 14 |
| Relative citation ratio | 0.46 |
| NIH percentile | 27 |
| Molecules | — |
Abstract
Recent studies have suggested glucagon-like peptide-1 (GLP-1) signaling to exert anti-inflammatory effects on endothelial cells, although the precise underlying mechanism remains to be elucidated. In the present study, we investigated whether PPARγ activation is involved in the GLP-1-mediated anti-inflammatory action on endothelial cells. When we treated HUVEC cells with 0.2ng/ml exendin-4, a GLP-1 receptor agonist, endogenous PPARγ transcriptional activity was significantly elevated, by approximately 20%, as compared with control cells. The maximum PPARγ activity enhancing effect of exendin-4 was observed 12h after the initiation of incubation with exendin-4. As H89, a PKA inhibitor, abolished GLP-1-induced PPARγ enhancement, the signaling downstream from GLP-1 cross-talk must have been involved in PPARγ activation. In conclusion, our results suggest that GLP-1 has the potential to induce PPARγ activity, partially explaining the anti-inflammatory effects of GLP-1 on endothelial cells. Cross-talk between GLP-1 signaling and PPARγ activation would have major impacts on treatments for patients at high risk for cardiovascular disease.
Verbatim abstract via PubMed 25109805 ↗